Targeting the virus with radioimmunotherapy in virus-associated cancers

Ekaterina Dadachova, Xing Guo Wang, Arturo Casadevall

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

"Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.

Original languageEnglish (US)
Pages (from-to)303-308
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume22
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Radioimmunotherapy
Viruses
Neoplasms
Virus Diseases
Papillomaviridae
Nasopharyngeal Neoplasms
Viral Antigens
Viral Tumor Antigens
Viral Proteins
Neoplasm Antigens
Human Herpesvirus 4
Hepatitis B virus
Uterine Cervical Neoplasms
Hepacivirus
Communicable Diseases
HIV-1
Hepatocellular Carcinoma
Lymphoma
Glycoproteins
Proteins

Keywords

  • Radioimmunotherapy
  • Viral infection
  • Virus-associated cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Targeting the virus with radioimmunotherapy in virus-associated cancers. / Dadachova, Ekaterina; Wang, Xing Guo; Casadevall, Arturo.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 22, No. 3, 06.2007, p. 303-308.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Wang, Xing Guo ; Casadevall, Arturo. / Targeting the virus with radioimmunotherapy in virus-associated cancers. In: Cancer Biotherapy and Radiopharmaceuticals. 2007 ; Vol. 22, No. 3. pp. 303-308.
@article{56bb5fdb767f400d9059c7da6dbd1921,
title = "Targeting the virus with radioimmunotherapy in virus-associated cancers",
abstract = "{"}Virus-associated cancer{"} (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are {"}self{"} proteins.",
keywords = "Radioimmunotherapy, Viral infection, Virus-associated cancer",
author = "Ekaterina Dadachova and Wang, {Xing Guo} and Arturo Casadevall",
year = "2007",
month = "6",
doi = "10.1089/cbr.2007.344",
language = "English (US)",
volume = "22",
pages = "303--308",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Targeting the virus with radioimmunotherapy in virus-associated cancers

AU - Dadachova, Ekaterina

AU - Wang, Xing Guo

AU - Casadevall, Arturo

PY - 2007/6

Y1 - 2007/6

N2 - "Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.

AB - "Virus-associated cancer" (VAC) refers to a cancer where viral infection results in the malignant transformation of the host's infected cells. Examples of viruses linked to cancers are the Epstein-Barr virus (EBV), which is associated with lymphomas, as well as nasopharyngeal and breast cancer; hepatitis B virus (HBV) and hepatitis C virus (HCV), which are both associated with hepatocellular carcinoma; and human papilloma viruses (HPVs), which are associated with cancer of the cervix. We have recently demonstrated that HIV-1-infected cells can be eliminated in vitro and in vivo by targeting viral glycoproteins expressed on the surface of infected cells with radiolabeled viral protein-specific monoclonal antibodies and proposed that this approach can be applicable to the broad range of viral infectious diseases. In VAC, the tumor cells can exhibit viral antigens both internally or on their surfaces. As a result, viral antigens in tumors represent a potential antigenic target that is clearly different from normal tissues. In principle, these proteins could be targeted by radioimmunotherapy (RIT). In this paper, we describe the potential of this approach and review some of the issues involved in the development of this approach. RIT of VAC is fundamentally different from the previously described uses of RIT, which have targeted tumor-associated antigens that are "self" proteins.

KW - Radioimmunotherapy

KW - Viral infection

KW - Virus-associated cancer

UR - http://www.scopus.com/inward/record.url?scp=34447503809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447503809&partnerID=8YFLogxK

U2 - 10.1089/cbr.2007.344

DO - 10.1089/cbr.2007.344

M3 - Article

C2 - 17651036

AN - SCOPUS:34447503809

VL - 22

SP - 303

EP - 308

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 3

ER -